Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231348 · ClinicalTrials.gov registry record · Phase 4
Nefazodone in the Treatment of Social Phobia
A Phase 4 study of Social Anxiety Disorder (SAD), sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00231348: Completed Phase 4 study of Social Anxiety Disorder (SAD), sponsored by Emory University.
NCT00231348 is a Phase 4 study of Social Anxiety Disorder (SAD) that has completed, run by Emory University. The registered enrollment target is 24 participants, below the 198-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00231348, a Phase 4 study of Social Anxiety Disorder (SAD), has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
Conditions Studied
Interventions
- DRUG Nefazodone
Study Locations (1)
Georgia
- Emory University Depatment of Psychiatry and Behavioral Sciences - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Est. Completion | 2000-04 |
| Phase | Phase 4 |
What the finished NCT00231348 record still lists
NCT00231348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 198-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 1 intervention - of which Nefazodone is the first listed.
NCT00231348 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00231348 about?
NCT00231348 is a clinical study titled "Nefazodone in the Treatment of Social Phobia". The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
What is the current status of trial NCT00231348?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. Estimated completion is 2000-04.
What conditions does trial NCT00231348 study?
This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).
What interventions are being tested in trial NCT00231348?
The interventions under investigation include: Nefazodone (DRUG).
Who is sponsoring clinical trial NCT00231348?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00231348 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder (SAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
RECRUITING · Phase 3
-
A Study of NTX-1472 in Social Anxiety Disorder
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant